A single dose of the DENV-1 candidate vaccine rDEN1δ30 is strongly immunogenic and induces resistance to a second dose in a randomized trial

PLoS Neglected Tropical Diseases

Volumn 5, Issue 8, 2011, Pages

  Durbin, Anna P ^a   Whitehead, Stephen S ^b   Shaffer, Donna ^a   Elwood, Dan ^a   Wanionek, Kimberli ^a   Thumar, Bhavin ^a   Blaney, Joseph E ^b   Murphy, Brian R ^b   Schmidt, Alexander C ^b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; DENGUE VACCINE; LIVE VACCINE; MONOVALENT RECOMBINANT DENGUE TYPE 1 DELTA30 VACCINE; NEUTRALIZING ANTIBODY; PLACEBO; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMORAL IMMUNITY; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; MACULOPAPULAR RASH; MALE; MYALGIA; NEUTROPENIA; NORMAL HUMAN; PAIN; RANDOMIZED CONTROLLED TRIAL; RETROORBITAL PAIN; SEROCONVERSION; SIDE EFFECT; SINGLE DRUG DOSE; VACCINATION; VIREMIA; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DENGUE; DENGUE VIRUS; IMMUNIZATION; IMMUNOLOGY; PHASE 1 CLINICAL TRIAL; SERODIAGNOSIS; VIROLOGY;

ADULT; ANTIBODIES, VIRAL; COHORT STUDIES; DENGUE; DENGUE VACCINES; DENGUE VIRUS; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; MALE; NEUTRALIZATION TESTS; PLACEBOS; VACCINES, ATTENUATED; VIREMIA;

EID: 80052416162     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001267     Document Type: Article

References (41)

1. Halstead SB, Suaya JA, Shepard DS, (2007) The burden of dengue infection. Lancet 369: 1410-1411.
2. Mammen MP, Pimgate C, Koenraadt CJ, Rothman AL, Aldstadt J, et al. (2008) Spatial and temporal clustering of dengue virus transmission in Thai villages. PLoS Med 5 (11): e205 doi:10.1371/journal.pmed.0050205.
3. Honorio NA, Nogueira RM, Codeco CT, Carvalho MS, Cruz OG, et al. (2009) Spatial evaluation and modeling of Dengue seroprevalence and vector density in Rio de Janeiro, Brazil. PLoS Negl Trop Dis 3 (11): e545 doi:10.1371/journal.pntd.0000545.
4. WHO (2009) Dengue Guidelines for diagnosis, treatment, prevention, and control. Geneva World Health Organization.
5. Kyle JL, Harris E, (2008) Global spread and persistence of dengue. Annu Rev Microbiol 62: 71-92.
6. Simmons CP, Farrar J, (2009) Changing patterns of dengue epidemiology and implications for clinical management and vaccines. PLoS Med 6 (9): e1000129 doi:10.1371/journal.pmed.1000129.
7. Nisalak A, Endy TP, Nimmannitya S, Kalayanarooj S, Thisayakorn U, et al. (2003) Serotype-specific dengue virus circulation and dengue disease in Bangkok, Thailand from 1973 to 1999. Am J Trop Med Hyg 68: 191-202.
8. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, et al. (2000) Dengue Viremia Titer, Antibody Response Pattern, and Virus Serotype Correlate with Disease Severity. J Infect Dis 181: 2-9.
9. Imrie A, Meeks J, Gurary A, Sukhbaatar M, Truong TT, et al. (2007) Antibody to dengue 1 detected more than 60 years after infection. Viral Immunol 20: 672-675.
10. Sabin A, (1952) Research on dengue during World War II. Am J Trop Med Hyg 1: 30-50.
11. Papaevangelou G, Halstead SB, (1977) Infections with two dengue viruses in Greece in the 20th century. Did dengue hemorrhagic fever occur in the 1928 epidemic? Am J Trop Med Hyg 80: 46-51.
12. Guzman MG, Kouri GP, Bravo J, Soler M, Vazquez S, et al. (1990) Dengue hemorrhagic fever in Cuba, 1981: a retrospective seroepidemiologic study. Am J Trop Med Hyg 42: 179-184.
13. Burke DS, Nisalak A, Johnson DE, Scott RM, (1988) A prospective study of dengue infections in Bangkok. Am J Trop Med Hyg 38: 172-180.
14. Morrison D, Legg TJ, Billings CW, Forrat R, Yoksan S, et al. (2010) A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J Infect Dis 201: 370-377.
15. Sabchareon A, Lang J, Chanthavanich P, Yoksan S, Forrat R, et al. (2002) Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am J Trop Med Hyg 66: 264-272.
16. Sabchareon A, Lang J, Chanthavanich P, Yoksan S, Forrat R, et al. (2004) Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children. Pediatr Infect Dis J 23: 99-109.
17. Sun W, Edelman R, Kanesa-Thasan N, Eckels KH, Putnak JR, et al. (2003) Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. Am J Trop Med Hyg 69: 24-31.
18. Sun W, Cunningham D, Wasserman SS, Perry J, Putnak JR, et al. (2009) Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naive adults. Hum Vaccin 5: 33-40.
19. Simasathien S, Thomas SJ, Watanaveeradej V, Nisalak A, Barberousse C, et al. (2008) Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children. Am J Trop Med Hyg 78: 426-433.
20. Lang J, (2009) Recent progress on sanofi pasteur's dengue vaccine candidate. J Clin Virol 46 (Suppl 2): S20-24.
21. Durbin AP, Karron RA, Sun W, Vaughn DW, Reynolds MJ, et al. (2001) Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3′-untranslated region. Am J Trop Med Hyg 65: 405-413.
22. Durbin AP, McArthur J, Marron JA, Blaney Jr. J.E., Thumar B, et al. (2006) The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers. Hum Vaccin 2: 167-173.
23. Durbin AP, Whitehead SS, McArthur J, Perreault JR, Blaney Jr. J.E., et al. (2005) rDEN4 Delta 30, a Live Attenuated Dengue Virus Type 4 Vaccine Candidate, Is Safe, Immunogenic, and Highly Infectious in Healthy Adult Volunteers. J Infect Dis 191: 710-718.
24. Durbin AP, McArthur JH, Marron JA, Blaney JE, Thumar B, et al. (2006) rDEN2/4Delta30(ME), A Live Attenuated Chimeric Dengue Serotype 2 Vaccine Is Safe and Highly Immunogenic in Healthy Dengue-Naive Adults. Hum Vaccin 2: 255-260.
25. Blaney Jr. J.E., Sathe NS, Goddard L, Hanson CT, Romero TA, et al. (2008) Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3′ untranslated region (3′-UTR) or by exchange of the DENV-3 3′-UTR with that of DENV-4. Vaccine 26: 817-828.
26. Whitehead SS, Blaney JE, Durbin AP, Murphy BR, (2007) Prospects for a dengue virus vaccine. Nat Rev Microbiol 5: 518-528.
27. Blaney Jr. J.E., Matro JM, Murphy BR, Whitehead SS, (2005) Recombinant, Live-Attenuated Tetravalent Dengue Virus Vaccine Formulations Induce a Balanced, Broad, and Protective Neutralizing Antibody Response against Each of the Four Serotypes in Rhesus Monkeys. J Virol 79: 5516-5528.
28. Whitehead SS, Falgout B, Hanley KA, Blaney Jr. J.E., Jr, Markoff L, et al. (2003) A Live, Attenuated Dengue Virus Type 1 Vaccine Candidate with a 30-Nucleotide Deletion in the 3′ Untranslated Region Is Highly Attenuated and Immunogenic in Monkeys. J Virol 77: 1653-1657.
29. Guirakhoo F, Kitchener S, Morrison D, Forrat R, McCarthy K, et al. (2006) Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccin 2: 60-67.
30. Guirakhoo F, Pugachev K, Zhang Z, Myers G, Levenbook I, et al. (2004) Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J Virol 78: 4761-4775.
31. Durbin AP, Whitehead SS, (2010) Dengue vaccine candidates in development. Curr Top Microbiol Immunol 338: 129-143.
32. Guy B, Saville M, Lang J, (2010) Development of Sanofi Pasteur tetravalent dengue vaccine. Hum Vaccin 6: 696-705.
33. Edelman R, Wasserman SS, Bodison SA, Putnak RJ, Eckels KH, et al. (2003) Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am J Trop Med Hyg 69: 48-60.
34. Kitchener S, Nissen M, Nasveld P, Forrat R, Yoksan S, et al. (2006) Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults. Vaccine 24: 1238-1241.
35. Kanesa-thasan N, Sun W, Kim-Ahn G, Van Albert S, Putnak JR, et al. (2001) Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine 19: 3179-3188.
36. Edelman R, Tacket CO, Wasserman SS, Vaughn DW, Eckels KH, et al. (1994) A live attenuated dengue-1 vaccine candidate (45AZ5) passaged in primary dog kidney cell culture is attenuated and immunogenic for humans. J Infect Dis 170: 1448-1455.
37. Haddy TB, Rana SR, Castro O, (1999) Benign ethnic neutropenia: what is a normal absolute neutrophil count? J Lab Clin Med 133: 15-22.
38. Hsieh MM, Everhart JE, Byrd-Holt DD, Tisdale JF, Rodgers GP, (2007) Prevalence of neutropenia in the U.S. population: age, sex, smoking status, and ethnic differences. Ann Intern Med 146: 486-492.
39. Reed WW, Diehl LF, (1991) Leukopenia, neutropenia, and reduced hemoglobin levels in healthy American blacks. Arch Intern Med 151: 501-505.
40. Lee IK, Liu JW, Yang KD, (2005) Clinical characteristics and risk factors for concurrent bacteremia in adults with dengue hemorrhagic Fever. Am J Trop Med Hyg 72: 221-226.
41. Halstead SB, Casals J, Shotwell H, Palumbo N, (1973) Studies on the immunization of monkeys against dengue. I. Protection derived from single and sequential virus infections. Am J Trop Med Hyg 22: 365-374.